Log in

BTAI BioXcel Therapeutics, Inc. OTC · United States

BioXcel Therapeutics (BTAI) news BTAI bankruptcy news

Latest BioXcel Therapeutics news

  1. Debt Financing

    BioXcel takes $1,250,000 in additional term loans from its lenders

    The amendment also lowers the minimum cash liquidity covenant to $250,000 and sets an August 31, 2026 deadline for a transaction acceptable to the lenders.

  2. Debt Financing

    BioXcel amends Oaktree credit agreement, sets August 21 deadline

    Oaktree Fund Administration, LLC is administrative agent. The amendment requires definitive transaction agreements by August 21, 2026 and sets the minimum liquidity amount at $3,000,000 from August 10, 2026.

  3. Debt Financing

    BioXcel amends Oaktree credit agreement and defers payment

    BioXcel's Eleventh Amendment moves a $9,016,914.47 payment to August 31, 2026, lowers the minimum liquidity amount to $6,250,000 and requires definitive transaction agreements by August 10, 2026.

Questions about BioXcel Therapeutics

Did BioXcel Therapeutics file for bankruptcy?

Our latest story on this, dated Aug 27, 2026: "BioXcel files Chapter 11 with Teva as $57.5 million stalking horse bidder". The story links the filing or release it is based on. Read the story.

What is the ticker symbol of BioXcel Therapeutics?

BioXcel Therapeutics, Inc. trades under the ticker BTAI on OTC.

Where is BioXcel Therapeutics listed?

BioXcel Therapeutics, Inc. is listed on OTC.

Which country or territory is BioXcel Therapeutics listed under?

Our directory records BioXcel Therapeutics, Inc. under United States.

Does aibio.space cover BioXcel Therapeutics?

aibio.space lists BioXcel Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

What is the latest BioXcel Therapeutics (BTAI) stock news?

Our latest story on BioXcel Therapeutics, dated Aug 27, 2026: "BioXcel files Chapter 11 with Teva as $57.5 million stalking horse bidder". BioXcel filed Chapter 11 on Aug 27 with Teva's $57.5 million upfront bid as the floor for a court auction. That upfront sum is below the company's $107,152 thousand of total debt at June 30. Source.

Does BioXcel Therapeutics have debt, a term loan or convertible notes?

Our latest debt story, dated Aug 24, 2026: "BioXcel takes $1,250,000 in additional term loans from its lenders". The amendment also lowers the minimum cash liquidity covenant to $250,000 and sets an August 31, 2026 deadline for a transaction acceptable to the lenders. Source.

How long will BioXcel Therapeutics's cash last?

From our story of Aug 27, 2026: BioXcel's quarterly report for the period ended June 30, 2026, already carried going-concern language. Source.

How can I follow BioXcel Therapeutics (BTAI) news?

Press Follow on this page to add BioXcel Therapeutics to your Following list, or subscribe to the aibio.space newsletter. We have published 4 stories naming BioXcel Therapeutics so far, in Debt Financing, Distress.

Investor discussion: BioXcel Therapeutics

Members talk about BioXcel Therapeutics (BTAI). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open OTC:BTAI on TradingView.

Listing details

BioXcel Therapeutics, Inc. is a public biotech or pharmaceutical company listed on OTC under the ticker BTAI, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
BioXcel Therapeutics, Inc.
Ticker
BTAI
Listing
OTC
Country or territory
United States

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.